Quick Answer
Lyell Immunopharma, Inc. reported Net Income Loss of -$274.45 million for the year ending 2025.
- Lyell Immunopharma, Inc. showed an increase of +20.0% in Net Income Loss from 2024 to 2025.
- This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Lyell Immunopharma, Inc.'s Net Income Loss has declined by 112.1%.
- Historical annual values: Fiscal year 2025: -$274.45 million | Fiscal year 2024: -$342.99 million | Fiscal year 2023: -$234.63 million | Fiscal year 2022: -$183.12 million | Fiscal year 2021: -$250.22 million | Fiscal year 2020: -$204.47 million | Fiscal year 2019: -$129.38 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: